We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
-11.49%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$143M
AUM Growth
-$31.2M
Cap. Flow
-$8.65M
Cap. Flow %
-6.06%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
1
DELISTED
NanoString Technologies, Inc.
NSTG
$58.2M 40.82%
3,959,440
– –
OXFD
2
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$24.8M 17.35%
2,153,092
– –
ATXS
3
DELISTED
Astria Therapeutics
ATXS
$21.8M 15.3%
45,875
– –
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$16.2M 11.33%
273,077
– –
VBIV
5
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$12.1M 8.5%
165,703
– –
TLOG
6
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
$8.04M 5.63%
4,644,705
– –
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
$1.53M 1.08%
63,017
– –
EVFM
8
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
– –
-11,905
Closed -$8.65M

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q4 2015 Portfolio in Review

As of Q4 2015, Clarus Ventures held 8 positions worth $143M, down 18% from $174M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures withdrew a net $8.65M in Q4 2015, closing 1 position. Its most notable exit was Evofem Biosciences, Inc. Common Stock, an estimated $8.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Clarus Ventures fully exited Evofem Biosciences, Inc. Common Stock in Q4 2015, selling an estimated $8.65M.
  • Clarus Ventures's ten largest holdings make up 100% of its $143M portfolio in Q4 2015.
  • Clarus Ventures opened 0 new positions and closed 1 in Q4 2015.
  • Clarus Ventures's portfolio value fell 18% quarter-over-quarter to $143M.

Based on Clarus Ventures's 13F filing for Q4 2015, filed 25 Jan 2016.